公开(公告)号：US20240165048A1

公开(公告)日：2024-05-23

申请号：US18526795

申请日：2023-12-01

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen Wright ,  Orrin Devinsky

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

CPC分类号： A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myocionic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US11987560B2

公开(公告)日：2024-05-21

申请号：US17356389

申请日：2021-06-23

申请人： CELGENE QUANTICEL RESEARCH, INC.

发明人： Young K. Chen ,  Toufike Kanouni ,  Stephen W. Kaldor ,  Jeffrey Alan Stafford ,  James Marvin Veal

IPC分类号： C07D239/47 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/551 ,  C07B59/00 ,  C07D239/36 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D471/10

CPC分类号： C07D239/47 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/551 ,  C07B59/002 ,  C07D239/36 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D471/10 ,  C07B2200/05

摘要： The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

公开(公告)号：US11981618B2

公开(公告)日：2024-05-14

申请号：US17262129

申请日：2019-07-24

申请人： AUTOTAC INC.

发明人： Yong Tae Kwon ,  Chang Hoon Ji ,  Srinivasrao Ganipisetti ,  Hee Yeon Kim ,  Su Ran Mun ,  Chan Hoon Jung ,  Eui Jung Jung ,  Ki Woon Sung

IPC分类号： C07C217/58 ,  A23L33/10 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/166 ,  A61K31/192 ,  A61K31/277 ,  A61K31/336 ,  A61K31/355 ,  A61K31/4015 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/428 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/565 ,  A61K39/395 ,  A61K47/54 ,  A61K47/55 ,  A61K47/68 ,  A61P25/28 ,  C07C43/23 ,  C07C47/575 ,  C07C235/06 ,  C07C237/06 ,  C07C275/24 ,  C07C279/12 ,  C07D303/18

CPC分类号： C07C217/58 ,  A23L33/10 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/166 ,  A61K31/192 ,  A61K31/277 ,  A61K31/336 ,  A61K31/355 ,  A61K31/4015 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/428 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/565 ,  A61K39/3955 ,  A61K47/54 ,  A61K47/55 ,  A61K47/6803 ,  A61K47/6849 ,  A61P25/28 ,  C07C43/23 ,  C07C47/575 ,  C07C235/06 ,  C07C237/06 ,  C07C275/24 ,  C07C279/12 ,  C07D303/18 ,  C07B2200/07

摘要： The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

公开(公告)号：US20240140958A1

公开(公告)日：2024-05-02

申请号：US18270616

申请日：2022-01-10

申请人： Tabomedex Biosciences, Inc.

发明人： Michael H. Serrano-Wu ,  Zhixiong Ye ,  Weihong Zheng

IPC分类号： C07D487/14 ,  A61K31/155 ,  A61K31/5377 ,  A61K31/551 ,  A61K33/243 ,  A61P35/00 ,  C07D519/00

CPC分类号： C07D487/14 ,  A61K31/155 ,  A61K31/5377 ,  A61K31/551 ,  A61K33/243 ,  A61P35/00 ,  C07D519/00

摘要： Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

公开(公告)号：US11963937B2

公开(公告)日：2024-04-23

申请号：US18320906

申请日：2023-05-19

申请人： GW Research Limited

发明人： Geoffrey Guy ,  Stephen Wright ,  Orrin Devinsky

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

CPC分类号： A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K31/352 ,  A61K2300/00 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/53 ,  A61K2300/00 ,  A61K31/5517 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/20 ,  A61K2300/00 ,  A61K31/423 ,  A61K2300/00 ,  A61K31/05 ,  A61K31/195 ,  A61K2300/00 ,  A61K2300/00

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US11938138B2

公开(公告)日：2024-03-26

申请号：US17371750

申请日：2021-07-09

申请人： Robi Mitra ,  Arnav Moudgil ,  Michael Nathaniel Wilkinson

发明人： Robi Mitra ,  Arnav Moudgil ,  Michael Nathaniel Wilkinson

IPC分类号： A61P35/00 ,  A61K31/506 ,  A61K31/551

CPC分类号： A61K31/551 ,  A61K31/506 ,  A61P35/00

摘要： Among the various aspects of the present disclosure is the provision of a methods for increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors.

公开(公告)号：US11925690B2

公开(公告)日：2024-03-12

申请号：US17251615

申请日：2019-06-13

申请人： AMPHISTA THERAPEUTICS LTD

发明人： Alessio Ciulli ,  Andrea Testa ,  Scott Hughes ,  Steven Peter Butcher

IPC分类号： A61K47/60 ,  A61K31/277 ,  A61K31/351 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/551 ,  A61K47/55 ,  C07D417/14 ,  C07D495/14

CPC分类号： A61K47/60 ,  A61K31/277 ,  A61K31/351 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/551 ,  A61K47/55 ,  C07D417/14 ,  C07D495/14

摘要： The invention provides for bifunctional molecules comprising an Rpn11 binding partner and a target protein binding partner. A bifunctional molecule according to the invention binds to Rpn11 and to the target protein, thereby facilitating degradation of the target protein bound to the target protein binding partner. The invention also provides for use of a bifunctional molecule for preventing or treating disease.

公开(公告)号：US20240058327A1

公开(公告)日：2024-02-22

申请号：US18183257

申请日：2023-03-14

申请人： Alkermes Pharma Ireland Limited

发明人： Jason M. PERRY ,  Daniel R. DEAVER ,  Magali B. HICKEY ,  Julius F. REMENAR ,  Jennifer VANDIVER

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61K9/10 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/551 ,  A61K31/5513 ,  A61K47/26 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24

CPC分类号： A61K31/496 ,  A61K9/0019 ,  A61K9/10 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/551 ,  A61K31/5513 ,  A61K47/26 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24

摘要： The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

公开(公告)号：US11865118B2

公开(公告)日：2024-01-09

申请号：US17263662

申请日：2019-07-29

申请人： MUTABILIS

发明人： Julien Barbion ,  Audrey Caravano ,  Sophie Chasset ,  Francis Chevreuil ,  Frédéric Le Strat ,  Christophe Simon ,  Julie Brias ,  Rémi Lebel

IPC分类号： A61K31/551 ,  A61P31/04 ,  A61K31/407 ,  A61K31/427 ,  A61K31/43 ,  A61K31/431 ,  A61K31/545 ,  A61K31/546 ,  C07D495/18 ,  C07D513/18

CPC分类号： A61K31/551 ,  A61K31/407 ,  A61K31/427 ,  A61K31/43 ,  A61K31/431 ,  A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07D495/18 ,  C07D513/18

摘要： The present invention relates to compounds of formula (I) and their use for treating or preventing a bacterial infection or as an antibacterial agent and/or as a β-lactamase inhibitor.

公开(公告)号：US20240000821A1

公开(公告)日：2024-01-04

申请号：US18102197

申请日：2023-01-27

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Carol W. Greider ,  Steven Wang

IPC分类号： A61K31/7076 ,  A61K31/4045 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/4745 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/655 ,  C12Q1/48 ,  G01N33/50

CPC分类号： A61K31/7076 ,  A61K31/4045 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/4745 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/655 ,  C12Q1/485 ,  G01N33/5011

摘要： The present invention relates generally to chromosome maintenance and cell viability, and more specifically, to the identification of kinases the inhibition of which blocks telomere elongation. In one aspect, the present invention provides methods for treating cancer. The methods generally comprise the administration of agents that interfere with the lengthening of telomeres in cancer. In a specific embodiment, a method of treating cancer in a subject by interfering with lengthening of telomeres in cancer cells comprises administering to the cells an effective amount of an inhibitor of casein kinase 1 (CK1), wherein the administration of the inhibitor leads to progressive telomere shortening in the cancer cell, thereby treating cancer in the subject. In another embodiment, the method can further comprise administering to the cells an effective amount of an inhibitor of bromodomain-containing protein 4 (BRD4) and/or an inhibitor of the MEK/ERK pathway.